USPTO Examiner SPENCE JENNIFER SUZANNE - Art Unit 1633

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18824576DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSSeptember 2024June 2025Allow930YesNo
18824588DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSSeptember 2024December 2024Allow420NoNo
18629423ENGINEERED IMMUNE CELLS WITH RECEPTOR CROSS-TALKApril 2024September 2025Allow1820NoNo
18411647TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENEJanuary 2024March 2025Allow1410NoNo
18391799DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSDecember 2023April 2024Allow410NoNo
18382284COMPOSITIONS AND METHODS FOR TREATING CANCEROctober 2023January 2025Allow1520YesNo
18361233CELL CULTURE MEDIUMJuly 2023May 2025Abandon2220YesNo
18007709TREATMENT OF CD30-POSITIVE CANCERDecember 2022March 2026Allow3920YesNo
17988257DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSNovember 2022September 2023Allow1010YesNo
17925411Single Domain Antibodies and Their Use in Cancer TherapiesNovember 2022December 2025Allow3710YesNo
17917770ENHANCED VIRAL TRANSDUCTION OF MAMMALIAN CELLS USING MATERIAL SCAFFOLDSOctober 2022February 2026Allow4010YesNo
17863832MEDIUM HAVING REDUCED OSMOTIC PRESSUREJuly 2022September 2025Abandon3910NoNo
17732581ANTI-ROBO1 CAR-T CELL, AND PREPARATION AND APPLICATION THEREOFApril 2022January 2026Abandon4510NoNo
17726517Modulation of Engineered Immune Cell Receptor Translation Using Noncoding Sequence ElementsApril 2022January 2026Abandon4510NoNo
17767806ENGINEERED IMMUNE CELLApril 2022December 2025Abandon4410NoNo
17763663ROR1 specific chimeric antigen receptors and their therapeutic applicationsMarch 2022August 2025Allow4110YesNo
17761723IMMUNE EFFECTOR CELL IN WHICH EXPRESSION IS REGULATED BY CYTOKINESMarch 2022November 2025Abandon4410NoNo
17761791GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH GENE ENCODING NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOFMarch 2022October 2025Abandon4310NoNo
17641404COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPYMarch 2022December 2025Allow4511YesNo
17649305KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTSJanuary 2022January 2026Allow4831YesYes
17626768ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAMEJanuary 2022February 2026Abandon4920NoNo
17572070Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyJanuary 2022April 2025Allow3910NoNo
17559985TREATMENT OF LIVER FAILURE BY EX VIVO REPROGRAMMED IMMUNE CELLSDecember 2021September 2024Abandon3211NoNo
17555581COMPOSITIONS AND METHODS FOR MAKING SENSORY NEURONSDecember 2021June 2024Allow3020NoNo
17620942T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53December 2021August 2025Allow4311NoNo
17553516METHOD FOR THE GENERATION OF A TRIVALENT ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATIONDecember 2021February 2026Abandon5011NoNo
17540777METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOFDecember 2021January 2024Allow2510NoNo
17525525GENETICALLY MODIFIED NATURAL KILLER CELLS AND METHODS OF USE THEREOFNovember 2021June 2025Abandon4321NoYes
17610083LOCKR-MEDIATED RECRUITMENT OF CAR T CELLSNovember 2021September 2025Abandon4610NoNo
17608587RESIN FILM FORMED BY SCAFFOLD MATERIAL FOR CELL CULTURE AND CONTAINER FOR CELL CULTURENovember 2021October 2024Allow3500NoNo
17607833CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED CD247 LOCUS, RELATED POLYNUCLEOTIDES AND METHODSOctober 2021May 2025Allow4310YesNo
17606756PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLSOctober 2021May 2025Abandon4210NoNo
17604954COMPOSITIONS AND METHODS FOR INCREASING MEGAKARYOCYTE PRODUCTIONOctober 2021April 2025Allow4220NoNo
17599831Treatment Of Intervertebral Disc DegenerationSeptember 2021February 2026Allow5320YesNo
17480466ENGINEERED IMMUNE CELLS WITH RECEPTOR CROSS-TALKSeptember 2021January 2024Allow2720YesNo
17472424METHODS FOR ENHANCING DIRECT REPROGRAMMING OF CELLSSeptember 2021November 2023Abandon2610NoNo
17446563ALIGNMENT OF CELLS IN ENGINEERED TISSUESAugust 2021January 2024Allow2820YesYes
17432380EXPANSION OF NATURAL KILLER AND CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLSAugust 2021June 2025Allow4620NoNo
17430676MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCEAugust 2021November 2025Allow5211YesNo
17429201METHODS FOR PREPARING EXTRACELLULAR VESICLES (EV) DEPLETEMEDIAAugust 2021March 2025Abandon4410NoNo
17392641Novel Animal Model For Laing Distal Myopathy (Mpd1) And Methods of Use ThereofAugust 2021October 2023Abandon2610NoNo
17390839DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLSJuly 2021November 2023Allow2711YesNo
17422885Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-CasJuly 2021March 2025Allow4411NoNo
17358760PSORIASIS AND OTHER AUTOIMMUNE DISEASES ANTIGEN IMMUNE MODULATOR (AIM) THERAPEUTIC PLATFORMJune 2021September 2024Abandon3920NoNo
17345885Enhancement of Mesenchymal Stem Cell Anti-inflammatory and Regenerative Activity Using mTOR InhibitorsJune 2021February 2024Abandon3220NoNo
17312259COMBINATION THERAPY FOR TREATING MUSCULAR DYSTROPHYJune 2021February 2026Abandon5630NoNo
17295256GENETICALLY MODIFIED ANIMAL WITH CANINE OR CHIMERIC PD-1May 2021February 2025Abandon4501NoNo
17294913COMPOSITION FOR RECONSTITUTING HUMAN SKIN TISSUE HAVING HAIR FOLLICLES, HUMAN SKIN TISSUE MODEL ANIMAL, AND PRODUCTION METHOD THEREOFMay 2021March 2025Abandon4611NoNo
17293415TRANSGENIC BETTAMay 2021July 2024Allow3820YesNo
17307235COMPOSITIONS AND METHODS FOR TREATING CANCERMay 2021July 2023Allow2611NoNo
17309154RECOMBINANT PARVOVIRAL VECTORS AND METHOD OF MAKING AND USE THEREOFApril 2021January 2025Allow4511NoNo
17231328ACTIVATION OF YAP SIGNALING FOR SENSORY RECEPTOR REGENERATIONApril 2021March 2024Abandon3520YesNo
17285084Chimeric antigen receptor carrying truncated or untruncated myeloid cell triggering receptor signaling structure and applications thereofApril 2021April 2025Abandon4820NoNo
17301637PROCESS TO PRODUCE KLOTHO PROTEIN IN VITROApril 2021October 2023Allow3020YesNo
17213611MODIFIED MAMMALIAN CELLSMarch 2021February 2024Allow3411NoNo
17209268USE OF MEMORY LYMPHOCYTE POPULATION IN LIVER CANCER TREATMENTMarch 2021December 2025Abandon5731NoNo
17204072METHODS FOR VIRAL INACTIVATION OF HUMAN PLATELET LYSATEMarch 2021December 2025Abandon5750NoNo
17275983TRANSPLANTATION OF MITOCHONDRIA INTO LYMPHOID ORGAN AND COMPOSITION THEREFORMarch 2021December 2024Allow4520YesNo
17195288AAV-MEDIATED SUBCELLULAR TARGETING OF HETEROLOGOUS RHODOPSINS IN RETINAL GANGLION CELLSMarch 2021January 2025Allow4610YesNo
16974427Tunable, simple, higher-yield, higher-rate, lower-cost recovery method of biopharmaceutical products from cell factoriesFebruary 2021June 2023Abandon2930NoNo
17144800Modified Cell Expressing Therapeutic Agent and Uses thereofJanuary 2021March 2024Abandon3811NoNo
17254472TARGETING OF MULTIPLE ANTIGENS WITH MULTIPLEX CAR T CELLS IN SOLID AND LIQUID MALIGNANCIESDecember 2020July 2025Allow5521NoNo
17112299TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENEDecember 2020September 2023Allow3411NoNo
17112911CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOFDecember 2020May 2024Allow4121NoNo
17108009Methods and materials for rapid preparation of 3D spheroids/organoidsDecember 2020March 2023Allow2810YesNo
17054939Method Of Reinforcing Efficacy Of Stem Cells Using EthionamideNovember 2020February 2024Allow3920YesNo
17049728METHOD FOR PRODUCING PRIMITIVE GUT TUBE CELLSOctober 2020November 2024Abandon4820NoNo
17049018METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOFOctober 2020February 2024Allow3910YesNo
17048021COMPOSITIONS AND METHODS FOR MULTIPLEXED TUMOR VACCINATION WITH ENDOGENOUS GENE ACTIVATIONOctober 2020August 2025Allow5831YesNo
17065814EGFR BINDING MOIETY-PRESENTING BACTERIOPHAGES FOR TUMOUR TREATMENTOctober 2020November 2023Abandon3811NoNo
16766836PLASMID DNA ENCODING BETA-ENDORPHIN, BACTERIAL PRODUCER, ANALGESIC AGENTOctober 2020July 2024Abandon5010YesNo
17044232RESCUING VOLTAGE-GATED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONSSeptember 2020June 2024Allow4510YesNo
17042349USE OF HOLLOW FIBERS TO OBTAIN BLOOD OR A BLOOD DERIVATIVE IMPOVERISHED FROM BLOOD CELLS AND PLATELETS DERIVED EXTRACELLULAR VESICLESSeptember 2020April 2024Allow4230YesNo
17021771DEVICE AND USES THEREOF FOR TREATING DIABETESSeptember 2020July 2023Allow3420NoNo
17012957GENETICALLY ENGINEERED T CELLS HAVING IMPROVED PERSISTENCE IN CULTURESeptember 2020February 2025Allow5451YesNo
17001817THREE-DIMENSIONAL CELL SPHEROID WITH HIGH PROLIFERATION ACTIVITY, AND PRODUCING METHOD AND USE THEREFORAugust 2020December 2025Abandon6050NoNo
16975364COMBINATION CANCER THERAPY WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGENAugust 2020June 2024Abandon4610NoNo
16965395CELL INDUCTION METHODJuly 2020August 2024Allow4921YesNo
16963095SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12July 2020March 2024Abandon4310NoNo
16961773LYMPHOCYTE PRODUCTION METHODJuly 2020March 2024Allow4430YesNo
16961483GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELL AS A PLATFORM FOR SYSTEMIC PROTEIN EXPRESSIONJuly 2020February 2024Allow4331NoNo
16958485CELL AGGREGATION SUPPRESSORJune 2020July 2025Abandon6031YesNo
16957918Compositions and Methods for Producing MegakaryocytesJune 2020June 2024Allow4721YesNo
16909283MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIESJune 2020January 2024Allow4220YesNo
16957086GENERATION OF INDUCED PLURIPOTENT CELLS BY CRISPR ACTIVATIONJune 2020July 2024Allow4831NoNo
16906937METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATIONJune 2020April 2024Allow4640NoNo
16770663INSERTABLE CULTURE CONTAINER AND KIT FOR THREE-DIMENSIONAL CELL CULTURE, AND THREE-DIMENSIONAL CELL CO-CULTURE METHOD USING SAMEJune 2020February 2023Allow3310YesNo
16769926CRISPR-CAS9 MODIFIED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS AND USES THEREOFJune 2020July 2024Allow5031NoNo
16893306METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURYJune 2020May 2024Allow4822YesNo
16764866SYSTEM AND METHOD FOR CARBON MONOXIDE ATMOSPHERE STORED BLOOD COMPONENTSMay 2020April 2024Abandon4701NoNo
16763834METHODS AND COMPOSITIONS FOR TREATING CANCER BY TARGETING THE CLEC2D-KLRB1 PATHWAYMay 2020February 2024Allow4521YesNo
16760004METHOD FOR IMPROVING STEM CELL MIGRATION USING ETHIONAMIDEApril 2020December 2023Allow4440YesNo
16615828System for DNA editing and uses thereofApril 2020November 2024Abandon5920NoNo
16648414CELL CULTURE MEDIUMMarch 2020December 2023Abandon4521NoNo
16806013CELL STRAIN FOR REDUCING PRODUCTION OF REPLICATION COMPETENT ADENOVIRUS, AND CONSTRUCTION METHOD AND USE THEREOFMarch 2020June 2023Allow4011YesNo
16631781COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIESJanuary 2020March 2024Allow5021NoNo
16629477METHOD FOR MANAGING PAINJanuary 2020October 2023Allow4521NoNo
16617429METHOD FOR THE ISOLATION OF SUBPOPULATIONS OF CARDIAC PROGENITOR CELLS AND RELATED USES IN THE MEDICAL FIELDNovember 2019February 2024Allow5130YesNo
16578026FUNCTIONALIZED WELL PLATE, METHODS OF PREPARATION AND USE THEREOFSeptember 2019January 2024Allow6021YesNo
16576601WNT-ACTIVATED ADIPOSE-DERIVED STEM CELL APPARATUSES, METHODS AND SYSTEMSSeptember 2019December 2025Allow6041YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SPENCE, JENNIFER SUZANNE.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
1
(50.0%)
Not Allowed After Appeal Filing
1
(50.0%)
Filing Benefit Percentile
77.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SPENCE, JENNIFER SUZANNE - Prosecution Strategy Guide

Executive Summary

Examiner SPENCE, JENNIFER SUZANNE works in Art Unit 1633 and has examined 86 patent applications in our dataset. With an allowance rate of 65.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner SPENCE, JENNIFER SUZANNE's allowance rate of 65.1% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by SPENCE, JENNIFER SUZANNE receive 2.21 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SPENCE, JENNIFER SUZANNE is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +47.0% benefit to allowance rate for applications examined by SPENCE, JENNIFER SUZANNE. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.8% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 39.1% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 126.3% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.